Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Naoko Hosono, Takahiro Yamauchi, Chi Sung-Gi, Hironori Arai, Kentaro Fukushima, Daisuke Ikeda, Satoshi Iyama, Akihiko Gotoh, Takayuki Ikezoe, Chikashi Yoshida, Goichi Yoshimoto, Junya Kanda, Naoto Takahashi, Emiko Sakaida, Kensuke Usuki, Yosuke Minami

Blood (2023) 142 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2023-184546

Published: 2023

Journal Articles

Distinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization

Blood (2023) 142 (Supplement 1): 430.

https://doi.org/10.1182/blood-2023-180518

Published: 2023

Journal Articles

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

Takeshi Kondo, Eri Matsuki, Tomoiku Takaku, Masaya Okada, Kazunori Murai, Chikashi Yoshida, Naoki Watanabe, Naoto Takahashi, Shinya Kimura, Itaru Matsumura

Blood (2023) 142 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2023-174169

Published: 2023

Journal Articles

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Blood (2021) 138 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2021-149483

Published: 2021

Journal Articles

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Blood (2021) 138 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2021-145483

Published: 2021

Journal Articles

A Single-Cell Atlas of Nonhematopoietic Cells in Human Lymph Node and Lymphoma Reveals Landscape of Stromal Remodeling

Blood (2021) 138 (Supplement 1): 447.

https://doi.org/10.1182/blood-2021-145718

Published: 2021

Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 4154.

https://doi.org/10.1182/blood-2019-130504

Published: 2019

Journal Articles

Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

Blood (2018) 132 (Supplement 1): 2160.

https://doi.org/10.1182/blood-2018-99-113788

Published: 2018

Journal Articles

Impact of Oral Voriconazole As Prophylaxis during Intensive Chemotherapy for Adult Patients with Acute Myeloid Leukemia: A Retrospective Cohort Study Using Japanese Administrative Database

Ikuyo Ota Tsutsumi, MD, Chikashi Yoshida, MD PhD, Masanori Seki, MD PhD, Takuya Komeno, MD MPH, PhD, Susumu Kunisawa, MD PhD, Kiyohide Fushimi, MD PhD, Yuichi Imanaka, MD DrMedSc, PhD MPH

Blood (2017) 130 (Supplement 1): 3371.

https://doi.org/10.1182/blood.V130.Suppl_1.3371.3371

Published: 2017

Journal Articles

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Chikashi Yoshida, MD PhD, Noriyoshi Iriyama, MDPhD, Yuho Najima, Shin Fujisawa, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD, PhD, Shinichiro Okamoto, MD PhD, Kimihiro Kawakami, MDPhD, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Kazuma Ohyashiki, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, MD PhD, Tadahiko Igarashi, MD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 1916.

https://doi.org/10.1182/blood.V128.22.1916.1916

Published: 2016

Journal Articles

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD, Kaichi Nishiwaki, MD PhD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 791.

https://doi.org/10.1182/blood.V128.22.791.791

Published: 2016

Journal Articles

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

Noriyoshi Iriyama, Shin Fujisawa, MD, Maki Hagihara, MDPhD, Chikashi Yoshida, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Shinichiro Okamoto, MD PhD, Kawakami Kimihiro, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD, Junichi Sakamoto, MDPhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 3142.

https://doi.org/10.1182/blood.V124.21.3142.3142

Published: 2014

Journal Articles

Odk-1201, One-Step RT-qPCR Major BCR-ABL/ABL mRNA Kit for the International Scale, with High Sensitivity to Detect Deeper MR

Itaru Matsumura, Hirohisa Nakamae, Chikashi Yoshida, MD PhD, Linda Fletcher, BS, Susan Branford, PhD, Daisuke Koga, Takayuki Sogabe, PhD, Yuzuru Kanakura, MD PhD, Tomoki Naoe, MDPhD

Blood (2014) 124 (21): 1805.

https://doi.org/10.1182/blood.V124.21.1805.1805

Published: 2014

Journal Articles

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Maki Hagihara, MDPhD, Noriyoshi Iriyama, MDPhD, Chikashi Yoshida, MD PhD, Shin Fujisawa, MD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Naoki Takezako, MD PhD, Kimihiro Kawakami, MD PhD, Shinichiro Okamoto, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Takashi Kumagai, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Junichi Sakamoto, MDPhD, Satoshi Morita, PhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 1795.

https://doi.org/10.1182/blood.V124.21.1795.1795

Published: 2014

Journal Articles

Multicenter Phase II Clinical Trial of Nilotinib for Patients with Imatinib-Resistant or Intolerant CML From the East Japan CML Study Group (EJCML) Trial: Evaluation of Molecular Responses by the BCR-ABL1 Mutational Status and Plasma Trough Concentration of Nilotinib

Blood (2012) 120 (21): 1360.

https://doi.org/10.1182/blood.V120.21.1360.1360

Published: 2012

Journal Articles

Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib

Eri Matsuki, MD, PhD, Takashi Kumagai, MD, Koiti Inokuchi, MD, PhD, Kazuteru Ohashi, M.D., Atsushi Shinagawa, MD, PhD, Jin Takeuchi, MD, PhD, Chikashi Yoshida, MD, PhD, Shinichiro Okamoto, MD, PhD, Hisashi Wakita, MD, Yasuji Kozai, MD, Yukari Shirasugi, MD, Shin Fujisawa, MD, Osamu Iwase, MD, Shingo Yano, MD, Kaichi Nishiwaki, MD, Koji Oba, MD, Junichi Sakamoto, MD, Hisashi Sakamaki, MD

Blood (2012) 120 (21): 691.

https://doi.org/10.1182/blood.V120.21.691.691

Published: 2012

Journal Articles

Dasatinib Induces a Higher Molecular Response in Japanese Patients with Chronic Myeloid Leukemia After Imatinib Failure Than in Western Populations: Kanto CML Study

Yoshihiro Hatta, MD, PhD, Koiti Inokuchi, MD, PhD, Takashi Kumagai, MD, Kazuteru Ohashi, MD, Atsushi Shinagawa, MD, Jin Takeuchi, MD, Shinichiro Okamoto, MD, PhD, Hisashi Wakita, MD, Yasuji Kouzai, MD, Yukari Shirasugi, MD, Chikashi Yoshida, MD, Koji Oba, MD, Junichi Sakamoto, MD, Hisashi Sakamaki, MD

Blood (2011) 118 (21): 4448.

https://doi.org/10.1182/blood.V118.21.4448.4448

Published: 2011

Journal Articles

Relevance of the Daily Dose of Imatinib Mesylate (IM) Rather Than Its Trough Plasma Concentration for Achieving Deep Molecular Response in Patients with Chronic Myeloid Leukemia.

Chikashi Yoshida, MD, PhD, Takuya Komeno, MD, MPH, PhD, Mitsuo Hori, MD, PhD, Tomofumi Kimura, MD, PhD, Masami Fujii, MD, PhD, Yasushi Okoshi, MD, PhD, Kazumi Suzukawa, MD, PhD, Shigeru Chiba, MD, PhD, Yuichi Hasegawa, MD, PhD, Harumi Yamamoto Mukai, MD, PhD, Takayoshi Ito, MD, PhD, Seiichi Shimizu, MD, PhD, Masaharu Kamoshita, MD, PhD, Daisuke Kudo, MD, Atsushi Shinagawa, MD, PhD, Norio Chikatsu, MD, PhD, Yuriko Monma, MD, Norimichi Watanabe, MD, PhD, Hiroshi Kojima, MD, PhD

Blood (2009) 114 (22): 1112.

https://doi.org/10.1182/blood.V114.22.1112.1112

Published: 2009

Journal Articles

Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1

Chikashi Yoshida, Fumiko Yoshida, Daniel E. Sears, Stephen M. Hart, Dai Ikebe, Akihiko Muto, Subham Basu, Kazuhiko Igarashi, Junia V. Melo

Blood (2006) 109 (3): 1211–1219.

https://doi.org/10.1182/blood-2005-12-040972

Published: 2006

Includes: Supplemental data

Journal Articles

Transcriptional Regulation of the Bach2 B-Cell Differentiation and Apoptotic Factor by the Bcr-Abl Oncoprotein.

Maria Makri, BSc, Chikashi Yoshida, MD, PhD, Akihiko Muto, PhD, Kazuhiko Igarashi, MD, PhD, Junia V Melo, MD, PhD

Blood (2005) 106 (11): 2991.

https://doi.org/10.1182/blood.V106.11.2991.2991

Published: 2005

NARROW

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Distinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

A Single-Cell Atlas of Nonhematopoietic Cells in Human Lymph Node and Lymphoma Reveals Landscape of Stromal Remodeling

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

Impact of Oral Voriconazole As Prophylaxis during Intensive Chemotherapy for Adult Patients with Acute Myeloid Leukemia: A Retrospective Cohort Study Using Japanese Administrative Database

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

Odk-1201, One-Step RT-qPCR Major BCR-ABL/ABL mRNA Kit for the International Scale, with High Sensitivity to Detect Deeper MR

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Multicenter Phase II Clinical Trial of Nilotinib for Patients with Imatinib-Resistant or Intolerant CML From the East Japan CML Study Group (EJCML) Trial: Evaluation of Molecular Responses by the BCR-ABL1 Mutational Status and Plasma Trough Concentration of Nilotinib

Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib

Dasatinib Induces a Higher Molecular Response in Japanese Patients with Chronic Myeloid Leukemia After Imatinib Failure Than in Western Populations: Kanto CML Study

Relevance of the Daily Dose of Imatinib Mesylate (IM) Rather Than Its Trough Plasma Concentration for Achieving Deep Molecular Response in Patients with Chronic Myeloid Leukemia.

Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1

Transcriptional Regulation of the Bach2 B-Cell Differentiation and Apoptotic Factor by the Bcr-Abl Oncoprotein.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only